Shakira Grant on AI impacting pathology and treatment decisions
Dr. Shakira Grant leads a discussion on AI impacting pathology and treatment decisions.
Community Oncology News
Community Oncology
News
Community Oncology News
Community Oncology
News
Hans Lee on increasing US representation in global clinical trials
Dr. Hans Lee leads a discussion on increasing US representation in global clinical trials.
Community Oncology News
Community Oncology
News
Marin Xavier on integrating new evidence into everyday practice
Dr. Marin Xavier leads a discussion on integrating new evidence into everyday practice.
Community Oncology News
Past Sessions
Community Oncology
News
Society Updates
Addressing funding gaps in blood cancer research
Dr. Gwen Nichols leads a discussion at 12:15 pm CST on July 13, 2026, on addressing funding gaps in blood cancer research.
Ambassador Program
News
Society Updates
1st SOHO Asia to be held in January 2026
SOHO Asia 2026 will focus on the latest advances in leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms (MPNs), featuring leading experts from across
Lymphoma
Mantle Cell Lymphoma
News
US FDA grants priority review to sonrotoclax in relapsed or refractory MCL
The US Food and Drug Administration accepted and granted priority review to a new drug application for sonrotoclax, a next-generation BCL2 inhibitor, for
Cellular Therapy
Lymphoma
News
US FDA approves liso-cel in relapsed or refractory MZL
The US Food and Drug Administration has approved lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or
Past Sessions
Community Oncology
News
Building partnerships between community and academic centers
Krish Patel presents at 1:15 pm CST on April 15, 2026, on building partnerships between community and academic centers.
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
News
FDA grants traditional approval to pirtobrutinib in relapsed or refractory CLL/SLL
The United States Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with
Past Sessions
Community Oncology
Dr. Jeffrey Matous on managing access to novel agents in the community setting
Held on March 18, 2026, from 12:30–1:00 PM CST with Jeffrey Matous presenting "Managing Access to Novel Agents in the Community Setting."